DRREDDY - Dr. Reddy's Laboratories Ltd. Share Price

Pharmaceuticals & Biotechnology

Sharesguru Stock Score

DRREDDY

69/100

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 4 years

₹1214.00+6.50(+0.54%)

Market Closed as of Apr 2, 2026, 15:30 IST

Select time range

Pros

Buy Backs: Company has bought back it's stock in the past which is a good thing.

Balance Sheet: Strong Balance Sheet.

Growth: Good revenue growth. With 44.9% growth over past three years, the company is going strong.

Size: It is among the top 200 market size companies of india.

Smart Money: Smart money has been increasing their position in the stock.

Profitability: Recent profitability of 15% is a good sign.

Cons

Momentum: Stock is suffering a negative price momentum. Stock is down -6.7% in last 30 days.

Technicals: SharesGuru indicator is Bearish.

Valuation
Market Cap	1.01 LCr
Price/Earnings (Trailing)	18.06
Price/Sales (Trailing)	2.79
EV/EBITDA	11.01
Price/Free Cashflow	54.7
MarketCap/EBT	14.03
Enterprise Value	1.04 LCr

Fundamentals
Revenue (TTM)	36.09 kCr
Rev. Growth (Yr)	5.8%
Earnings (TTM)	5.52 kCr
Earnings Growth (Yr)	-15.3%

Profitability
Operating Margin	20%
EBT Margin	20%
Return on Equity	15.18%
Return on Assets	10.16%
Free Cashflow Yield	1.83%

Growth & Returns
Price Change 1W	-7.2%
Price Change 1M	-6.7%
Price Change 6M	-3.2%
Price Change 1Y	4.8%
3Y Cumulative Return	9.3%
5Y Cumulative Return	5.6%
7Y Cumulative Return	11.8%
10Y Cumulative Return	7.3%

Cash Flow & Liquidity
Cash Flow from Investing (TTM)	-5.1 kCr
Cash Flow from Operations (TTM)	4.64 kCr
Cash Flow from Financing (TTM)	1.19 kCr
Cash & Equivalents	990.6 Cr
Free Cash Flow (TTM)	1.89 kCr
Free Cash Flow/Share (TTM)	22.67

Balance Sheet
Total Assets	54.37 kCr
Total Liabilities	18 kCr
Shareholder Equity	36.37 kCr
Current Assets	27.96 kCr
Current Liabilities	15.1 kCr
Net PPE	9.12 kCr
Inventory	7.58 kCr
Goodwill	1.4 kCr

Capital Structure & Leverage
Debt Ratio	0.08
Debt/Equity	0.12
Interest Coverage	20.53
Interest/Cashflow Ops	16.17

Dividend & Shareholder Returns
Dividend/Share (TTM)	8
Dividend Yield	0.65%
Shares Dilution (1Y)	0.00%
Shares Dilution (3Y)	0.20%

Technical Indicators
RSI (14d)	38.17
RSI (5d)	25.46
RSI (21d)	39.51
MACD Signal	Sell
Stochastic Oscillator Signal	Hold
SharesGuru Signal	Sell
RSI Signal	Hold
RSI5 Signal	Buy
RSI21 Signal	Hold
SMA 5 Signal	Sell
SMA 10 Signal	Sell
SMA 20 Signal	Sell
SMA 50 Signal	Sell
SMA 100 Signal	Sell

Description	Share	Value
a) Global Generics	89.4%	8 kCr
b) Pharmaceutical Services and Active Ingredients	10.6%	947.2 Cr
Total		8.9 kCr

Shareholder Name	Holding %
LIFE INSURANCE CORPORATION OF INDIA P & GS FUND	11.79%
GVP Family Trust	11.51%
J P Morgan Chase Bank NA	10.87%
VSD Family Trust	9.06%
ICICI PRUDENTIAL VALUE DISCOVERY FUND	4.56%
KALLAM SATISH REDDY HUF	3.31%
NPS TRUST-A/C SBI PENSION FUND SCHEME TAX SAVER-TIER 2	2.44%
GUNUPATI VENKATESWARA PRASAD HUF	1.52%
SATISH REDDY KALLAM	1.21%
ANURADHA GUNUPATI	0.01%
G V PRASAD	0%
K SHRAVYA REDDY	0%
K VISHAL REDDY	0%
VSD Holdings & Advisory LLP	0%
APS Trust	0%
SKR Family Trust	0%
KVR Family Trust	0%
Serendipity Family Trust	0%
Malli G Family Trust	0%
SRG Family Trust	0%

Ticker	Name	Mkt Cap	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
SUNPHARMA	Sun Pharmaceutical Industries	4.14 LCr	58.94 kCr	-1.50%	+1.60%	37.93	7.03	-	-
DIVISLAB	Divi's Lab	1.57 LCr	10.75 kCr	-7.80%	+6.40%	63.26	14.58	-	-
LUPIN	Lupin	1.04 LCr	26.49 kCr	-1.60%	+16.30%	22.36	3.92	-	-
CIPLA	Cipla	96.9 kCr	29.37 kCr	-11.20%	-16.90%	21.31	3.3	-	-
AUROPHARMA	Aurobindo Pharma	77.83 kCr	33.73 kCr	+10.70%	+18.20%	22.32	2.31	-	-

Description	(%) Q/Q	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020
Revenue From Operations	16.5%	32,644	28,011	24,670	21,545	19,048	17,517
Other Income	22.7%	1,097	894	1,056	484	291	621
Total Income	16.7%	33,741	28,905	25,725	22,030	19,339	18,138
Cost of Materials	26.6%	5,684	4,490	4,220	4,312	4,296	2,985
Purchases of stock-in-trade	10.1%	4,841	4,399	3,367	3,484	2,574	2,546
Employee Expense	10.9%	5,580	5,030	4,647	3,886	3,630	3,380
Finance costs	65.9%	283	171	143	96	97	98
Depreciation and Amortization	15.9%	1,704	1,470	1,250	1,165	1,229	1,163
Other expenses	24.8%	8,537	6,839	6,016	6,450	5,469	6,112
Total Expenses	20.1%	26,083	21,719	19,714	19,038	16,503	16,308
Profit Before exceptional items and Tax	6.6%	7,658	7,186	6,012	2,991	2,836	1,830
Total profit before tax	6.6%	7,658	7,186	6,012	2,991	2,836	1,830
Current tax	16%	2,258	1,946	814	1,101	817	662
Deferred tax	5.9%	-303.8	-322.8	727	-222.4	115	-801.9
Total tax	20.4%	1,954	1,623	1,541	879	932	-140.3
Total profit (loss) for period	2.6%	5,725	5,578	4,507	2,182	1,952	2,026
Other comp. income net of taxes	406.3%	205	-65.6	-12.1	-289.8	540	-65
Total Comprehensive Income	7.6%	5,930	5,512	4,495	1,893	2,492	1,961
Earnings Per Share, Basic	1.3%	67.89	67.044	54.294	26.314	23.534	24.444
Earnings Per Share, Diluted	1.3%	67.79	66.918	54.18	26.242	23.468	24.398

Description	(%) Q/Q	Dec-2025	Sep-2025	Jun-2025	Mar-2025	Dec-2024	Sep-2024
Revenue From Operations	-0.8%	8,753	8,828	8,572	8,528	8,381	8,038
Other Income	-17%	269	324	290	522	150	308
Total Income	-1.4%	9,022	9,152	8,862	9,050	8,531	8,346
Cost of Materials	26.7%	1,826	1,441	2,036	1,716	1,453	1,287
Purchases of stock-in-trade	-11.7%	1,542	1,746	1,216	1,128	1,051	1,283
Employee Expense	9.4%	1,588	1,452	1,504	1,401	1,366	1,399
Finance costs	3.3%	94	91	83	66	82	76
Depreciation and Amortization	3.2%	521	505	476	455	471	397
Other expenses	-2.7%	2,182	2,243	2,088	2,280	2,160	2,196
Total Expenses	0.9%	7,481	7,414	6,958	7,051	6,661	6,434
Profit Before exceptional items and Tax	-11.3%	1,541	1,738	1,905	2,000	1,870	1,911
Total profit before tax	-11.3%	1,541	1,738	1,905	2,000	1,870	1,911
Current tax	12%	207	185	1,026	432	533	771
Deferred tax	-34.7%	146	223	-531	-13.8	-62.9	-195.8
Total tax	-13.3%	354	408	495	418	470	576
Total profit (loss) for period	-11%	1,190	1,337	1,410	1,587	1,404	1,342
Other comp. income net of taxes	58.6%	177	112	205	109	-202.4	296
Total Comprehensive Income	-5.7%	1,367	1,449	1,615	1,696	1,202	1,638
Earnings Per Share, Basic	-10.9%	14.53	16.18	17.04	19.12	16.97	3.016
Earnings Per Share, Diluted	-10.9%	14.52	16.17	17.02	19.1	16.94	3.01

Description	(%) Q/Q	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020
Revenue From Operations	18.6%	23,115	19,484	16,962	14,405	13,349	11,850
Other Income	16.4%	1,003	862	591	482	801	743
Total Income	18.5%	24,119	20,346	17,554	14,887	14,150	12,594
Cost of Materials	15.4%	3,800	3,292	3,161	3,378	3,266	2,556
Purchases of stock-in-trade	22.8%	2,440	1,987	1,779	2,057	1,252	1,117
Employee Expense	6.5%	3,288	3,086	2,833	2,435	2,270	2,030
Finance costs	419%	110	22	17	38	47	48
Depreciation and Amortization	6.5%	1,039	976	923	814	835	789
Other expenses	17.5%	6,380	5,432	4,845	4,331	3,819	3,377
Total Expenses	16%	16,883	14,555	13,688	12,663	11,094	9,818
Profit Before exceptional items and Tax	25%	7,236	5,791	3,866	2,224	3,056	2,776
Total profit before tax	25%	7,236	5,791	3,866	2,224	3,056	2,776
Current tax	31.4%	1,790	1,362	864	393	540	484
Deferred tax	9.2%	96	88	389	208	330	-645.8
Total tax	30.2%	1,886	1,449	1,253	601	870	-161.9
Total profit (loss) for period	23.2%	5,349	4,342	2,613	1,623	2,186	2,938
Other comp. income net of taxes	126.8%	9.8	-31.8	-53.4	51	54	-43.6
Total Comprehensive Income	24.3%	5,359	4,310	2,559	1,674	2,240	2,894
Earnings Per Share, Basic	23.5%	64.22	52.19	31.474	19.57	26.368	35.446
Earnings Per Share, Diluted	23.6%	64.13	52.092	31.406	19.516	26.292	35.376

Description	(%) Q/Q	Dec-2025	Sep-2025	Jun-2025	Mar-2025	Dec-2024	Sep-2024
Revenue From Operations	-7.3%	4,283	4,619	7,810	5,563	5,015	6,696
Other Income	-1.1%	360	364	398	414	235	208
Total Income	-6.8%	4,643	4,983	8,208	5,977	5,250	6,904
Cost of Materials	5.8%	1,067	1,009	1,136	943	1,012	934
Purchases of stock-in-trade	6.2%	769	724	664	535	508	656
Employee Expense	10.6%	960	868	887	797	794	840
Finance costs	25%	41	33	19	31	43	28
Depreciation and Amortization	6.5%	314	295	280	264	265	260
Other expenses	-1.4%	1,518	1,540	1,499	1,763	1,545	1,637
Total Expenses	1.6%	4,539	4,466	4,272	4,416	4,131	4,263
Profit Before exceptional items and Tax	-80%	104	516	3,936	1,562	1,119	2,641
Total profit before tax	-80%	104	516	3,936	1,562	1,119	2,641
Current tax	-84.4%	13	78	942	364	256	703
Deferred tax	-100.8%	0.6	51	33	-3.2	14	55
Total tax	-89.8%	14	129	975	361	270	759
Total profit (loss) for period	-76.7%	91	387	2,961	1,201	849	1,882
Other comp. income net of taxes	106.7%	7	-88.7	18	71	-58.3	-6.6
Total Comprehensive Income	-67.4%	98	299	2,980	1,271	791	1,876
Earnings Per Share, Basic	-97.5%	1.09	4.65	35.59	14.41	10.2	4.52
Earnings Per Share, Diluted	-97.5%	1.09	4.65	35.54	14.39	10.18	4.512

Description	(%) Q/Q	Sep-2025	Mar-2025	Sep-2024	Mar-2024	Sep-2023	Mar-2023
Cash and cash equivalents	-32.4%	991	1,465	1,133	711	1,354	578
Current investments	17.7%	3,922	3,331	3,065	4,405	3,865	4,450
Total current financial assets	13%	17,184	15,203	15,125	16,432	14,296	14,046
Inventories	6.7%	7,582	7,108	7,204	6,355	5,659	4,867
Current tax assets	-	0	0	228	-	30	269
Total current assets	11.7%	27,956	25,018	25,048	24,805	21,770	20,694
Property, plant and equipment	25%	9,119	7,298	6,726	6,249	5,850	5,654
Capital work-in-progress	-16.8%	1,997	2,399	1,852	1,351	1,151	975
Goodwill	6.9%	1,404	1,314	1,316	550	541	547
Non-current investments	9.2%	261	239	120	106	186	66
Total non-current financial assets	-50.3%	561	1,127	237	227	259	139
Total non-current assets	8.2%	26,417	24,408	21,681	14,058	13,040	11,591
Total assets	10%	54,373	49,427	46,728	38,864	34,809	32,285
Borrowings, non-current	-100.3%	0	380	380	380	604	128
Total non-current financial liabilities	50.7%	1,214	806	1,017	599	604	128
Provisions, non-current	34.5%	40	30	0	24	19	20
Total non-current liabilities	17.5%	2,896	2,465	2,664	1,021	906	427
Borrowings, current	18.2%	4,496	3,804	4,002	1,272	719	1,219
Total current financial liabilities	15.7%	12,309	10,636	10,765	7,518	6,337	6,419
Provisions, current	-3.2%	751	776	636	692	630	652
Current tax liabilities	152.3%	763	303	509	234	398	214
Total current liabilities	15.9%	15,104	13,034	12,921	9,588	8,406	8,572
Total liabilities	16.1%	18,000	15,499	15,585	10,609	9,313	8,999
Equity share capital	1.2%	84	83	83	83	83	83
Non controlling interest	-5%	359	378	394	0	0	-
Total equity	7.2%	36,373	33,927	31,143	28,255	25,497	23,286
Total equity and liabilities	10%	54,373	49,427	46,728	38,864	34,809	32,285

Description	(%) Q/Q	Sep-2025	Mar-2025	Sep-2024	Mar-2024	Sep-2023	Mar-2023
Cash and cash equivalents	-53.6%	149	320	98	201	112	112
Current investments	13.4%	3,270	2,883	2,533	4,118	3,584	4,298
Total current financial assets	22.4%	12,196	9,964	10,591	12,183	11,089	9,526
Inventories	6.3%	4,862	4,576	4,568	4,019	3,614	3,043
Current tax assets	-	-	-	0	-	0	255
Total current assets	17.5%	19,391	16,503	16,945	17,816	16,181	14,043
Property, plant and equipment	19.5%	7,008	5,865	5,442	5,109	4,801	4,738
Capital work-in-progress	-20.9%	1,706	2,156	1,575	1,172	1,048	899
Goodwill	0%	85	85	85	85	85	85
Non-current investments	8.1%	11,146	10,310	9,969	3,203	3,303	3,142
Loans, non-current	0%	1.4	1.4	1.5	62	61	1.1
Total non-current financial assets	2.2%	11,413	11,168	10,057	3,356	3,418	3,197
Total non-current assets	6.5%	23,200	21,788	19,714	12,543	11,806	11,332
Total assets	11.2%	42,591	38,291	36,660	30,359	27,986	25,375
Borrowings, non-current	-	0	0	0	0	44	29
Total non-current financial liabilities	242.7%	258	76	48	50	44	29
Provisions, non-current	150%	12	5.4	9.2	9.3	7.9	7.9
Total non-current liabilities	26.8%	991	782	653	580	567	461
Borrowings, current	8.2%	3,663	3,386	3,710	710	36	22
Total current financial liabilities	14.4%	8,618	7,532	7,841	4,520	3,649	3,337
Provisions, current	-17.1%	282	340	298	328	298	305
Current tax liabilities	538.5%	499	79	407	67	179	0
Total current liabilities	16.6%	10,087	8,652	9,099	5,538	4,701	4,440
Total liabilities	17.4%	11,078	9,434	9,752	6,118	5,268	4,901
Equity share capital	1.2%	84	83	83	83	83	83
Total equity	9.2%	31,513	28,857	26,908	24,241	22,718	20,474
Total equity and liabilities	11.2%	42,591	38,291	36,660	30,359	27,986	25,375

Description	(%) Q/Q	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020
Finance costs	65.9%	283	171	143	96	-	-
Change in inventories	30.8%	-1,275.3	-1,844.5	-265.4	-532.8	-	-
Depreciation	15.9%	1,704	1,470	1,250	1,165	-	-
Impairment loss / reversal	24100%	169	0.3	70	930	-	-
Unrealised forex losses/gains	136.8%	21	-53.3	-92.5	-75.8	-	-
Adjustments for interest income	17.6%	268	228	118	96	-	-
Share-based payments	2.5%	42	41	40	59	-	-
Net Cashflows from Operations	1.4%	6,642	6,548	6,959	3,554	-	-
Income taxes paid (refund)	-0.3%	1,999	2,005	1,071	744	-	-
Net Cashflows From Operating Activities	2.2%	4,643	4,543	5,887	2,811	-	-
Cashflows used in obtaining control of subsidiaries	-	5,310	0	0	33	-	-
Cash payment for investment in partnership firm or association of persons or LLP	15400%	32	1.2	0	0	-	-
Proceeds from sales of PPE	-52.4%	51	106	8.2	37	-	-
Purchase of property, plant and equipment	67.7%	2,750	1,640	1,132	1,466	-	-
Proceeds from sales of intangible assets	-	0	0	0	295	-	-
Purchase of intangible assets	-37.6%	689	1,103	754	439	-	-
Dividends received	-102.3%	0	44	0	0	-	-
Interest received	152.6%	337	134	78	87	-	-
Net Cashflows From Investing Activities	-26.6%	-5,102.1	-4,028.3	-4,137.1	-2,638.7	-	-
Proceeds from issuing shares	-77.2%	19	80	16	33	-	-
Payments to acquire or redeem entity's shares	-	139	0	0	0	-	-
Proceeds from borrowings	163.8%	2,449	929	0	352	-	-
Repayments of borrowings	-100.3%	0	380	1,938	0	-	-
Payments of lease liabilities	12.3%	129	115	102	78	-	-
Dividends paid	0.2%	666	665	498	415	-	-
Interest paid	53.5%	348	227	185	134	-	-
Other inflows (outflows) of cash	-	0	0	21	0	-	-
Net Cashflows from Financing Activities	414.1%	1,186	-376.3	-2,686.1	-242.2	-	-
Effect of exchange rate on cash eq.	404.3%	22	-5.9	29	73	-	-
Net change in cash and cash eq.	466.7%	749	133	-907.3	3.2	-	-

DRREDDY - Dr. Reddy's Laboratories Ltd. Share Price

DRREDDY

Price to Sales Ratio

Revenue (Last 12 mths)

Net Income (Last 12 mths)

DRREDDY

DRREDDY - Dr. Reddy's Laboratories Ltd. Share Price

DRREDDY

Valuation

Fundamentals

Profitability

Price to Sales Ratio

Revenue (Last 12 mths)

Net Income (Last 12 mths)

Growth & Returns

Cash Flow & Liquidity

Balance Sheet

Capital Structure & Leverage

Dividend & Shareholder Returns

DRREDDY

Investor Care

Financial Health

Technical Indicators

Share Holdings

Holding Pattern

Share Holding Details

Overall Distribution

Ownership Distribution

What does Dr. Reddy's Laboratories Ltd. do?

Important Disclosure & Data Context

Valuation

Fundamentals

Profitability

Growth & Returns

Cash Flow & Liquidity

Balance Sheet

Capital Structure & Leverage

Dividend & Shareholder Returns

Investor Care

Financial Health

Technical Indicators

Share Holdings

Holding Pattern

Share Holding Details

Overall Distribution

Ownership Distribution

What does Dr. Reddy's Laboratories Ltd. do?

Important Disclosure & Data Context